Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2006-02-14
2006-02-14
Mertz, Prema (Department: 1646)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C530S350000, C435S069100, C435S325000, C435S471000, C435S071100, C435S071200, C435S252300, C435S254110, C435S320100
Reexamination Certificate
active
06998475
ABSTRACT:
The present invention relates to variants of TRAF2 which demonstrate the ability to inhibit the TNF α signaling path-way. In particular, applicants have isolated a splice variant of TRAF2 referred to hereinafter as “TRAF2 truncated” or “TRAF2TR” and a TRAF2 expression construct with enhanced dominant negative properties, hereafter referred to as “TRAF2 truncated-deleted” or “TRAF2TD”. Both TRAF2TR and TRAF2TD have the ability to inhibit the TNF α signaling pathway and in TRAF2TD, this ability is greatly enhanced, greatly reducing the response to TNF α binding.
REFERENCES:
Eck & Wilson in Goodman & Gilman's The Pharmacological Basis of Therapeutics, Ninth Edition, McGraw-Hill New York, 1996.
Brink, et al., Tumor Necrosis Factor Receptor (TNFR)-associated Factor 2A (TRAF2A), a TRAF2 Splice Variant with an Extended Ring Finger Domain that Inhibits TNFR2-mediated NF-kB Activation, The Journal of Biological Chemistry, Feb. 13, 1998, vol. 273, No. 7, pp. 4129-4134.
Takeuchi et al., Distinct Domains for Nuclear Factor-kBActivation and Association with Tumor Necrosis Factor Signaling Proteins, The Journal of Biological Chemistry, Aug. 16, 1996, vol. 271, No. 33, pp. 19935-19942.
Song, et al., Tumor Necrosis Factor (TNF)-mediated Kinase Cascades: Bifurcation of Nuclear Factor-kB and c-jun N-terminal Kinase (JNK/SAPK) Pathways at TNF Receptor-associated Factor 2, Proc. Natl. Acad. Sci., vol. 94, pp. 9792-9796, Sep. 1997, Immunology.
Min, et al., TNF Initiates E-Selectin Transcription in Human Endothelial Cells Through Parallel TRASF-NF-kB and TRAF-RAC/CDC42-JNK-c-Jun/ATF2 Pathways, The Journal of Immunology, 1997, vol. 159, pp. 3508-3518.
Bryant, et al., Cardiac Failure in Transgenic Mice with Myocardial Expression of Tumor Necrosis Factor-a, Circulation vol. 97, No. 14, pp. 1375-1381, Apr. 1998.
Kubota, et al., Dilated Cardiomyopathy in Transgenic Mice with Cardiac-Specific Overexpression of Tumor Necrosis Factor-a, Circulation Research, vol. 81, No. 4, pp. 627-635, Oct. 1997.
Ursula Muller-Werdan et al., Cardiodepression by Tumor Necrosis Factor-alpha, Europcan Cytokine Network, vol. 9, Issue 4, pp. 689-692, Dec. 1998.
Aukrust, et al., Cytokine Network in Congestive Heart Failure Secondary to Ischemic or Idiopathic Dilated Cardiomypathy, The American Journal of Cardiology, volumne 83, No. 3, pp. 376-382, 1999.
Palermo et al., Transgenic Remodeling of the Contractile Apparatus in the Mammalian Heart, Circulation Research, vol. 78, No. 3, pp. 504-509, Mar. 1996.
Shani, Moshe, Tissue-specific expression of rat myosin light-chain 2 gene in transgenic mice, Nature, vol. 314, No. 21, pp. 283-286, Mar. 1985.
Jeyaseelan, et al., A Novel Cardiac-Restricted Target for Doxorubicin: Carp, A Nuclear Modulator of Gene Expression in Cardiac Progenitor Cells and Cardiomyocytes, The Journal of Biological Chemistry, vol. 272, No. 36, pp. 22800-22808, Sep. 5, 1997.
Rothe et al.,A Novel Family of Putative Signal Transducers Associated With the Cytoplasmic Domain of the 75 kDa Tumor Necrosis Factor Receptor, Cell, vol. 78: p. 681-692 (Aug. 26, 1994).
Hsu et al., TRADd-TRAF2 and TRADD-FADD Interactions Define Two Distinct TNF Receptor 1 Signal Transduction Pathways, Cell, vol. 84: p. 299-308 (Jan. 26, 1996).
Rothe et al.,TRAF2-Medicated Activation of NF-kB by TNF Receptor 2 and CD40,PNAS vol. 269: p.. 1424-1427 (Sep. 8, 1995).
Le, et al.,CD30/TNF Receptor-Associated Factor Interaction: NF-kB Activation and Binding Specificity, PNAS vol 93, p. 9699-9703 (Sep. 1996).
Hori et al.,A Novel Domain in the CD30 Cytoplasmic Tail mediates NfkB Activation, International Immunology vol. 10, No. 2, p. 203-210 (Feb. 2, 1998).
Duckett, et al.,Inducgtion of Nuclear FactorkB by the CD 30 Receptor is Mediated by TRAF1 and TRAF2, Mol. and Cell. Biol. vol. 17, No. 3, p. 1535-1542 (Mar. 1997).
Dadgostar et al.,An Intact zinc Ring Finger is Required for tumor Necrosis Factor Receptor-Associated Factor-Mediated Nuclear Factor-kB Activation But Is Dispensable for C-Jun-N-terminal Kinase Signaling, J. Biol. Chem. vol. 272, No. 38, p. 24775-24780 (Sep. 18, 1998).
Cao et al.,TRAF6 is a Signal Transducer for Interleukin-1, Nature, vol. 383 p. 443-446 (Oct. 1996).
Clark Kenneth L.
Guo Kun
Ivashchenko Yuri D.
Pagnoni Marco F.
Searfoss, III George H.
Centelion SAS
Mertz Prema
Synnestvedt & Lechner LLP
LandOfFree
Variants of traf2 which act as an inhibitor of tnf-alpha... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Variants of traf2 which act as an inhibitor of tnf-alpha..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Variants of traf2 which act as an inhibitor of tnf-alpha... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3695911